| Literature DB >> 25885207 |
Luisa Del Río-Ospina1,2, Sara Cecilia Soto-De León3,4, Milena Camargo5,6, Darwin Andrés Moreno-Pérez7,8, Ricardo Sánchez9,10, Antonio Pérez-Prados11, Manuel Elkin Patarroyo12,13, Manuel Alfonso Patarroyo14,15.
Abstract
BACKGROUND: Analysing human papillomavirus (HPV) viral load is important in determining the risk of developing cervical cancer (CC); most knowledge to date regarding HPV viral load and cervical lesions has been related to HPV-16. This study evaluated the association between the viral load of the six most prevalent high-risk viral types in Colombia and cervical intraepithelial neoplasia (CIN) frequency.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25885207 PMCID: PMC4355361 DOI: 10.1186/s12885-015-1126-z
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Figure 1Flowchart of the studied population.*Inclusion criteria: women who had both a colposcopy result and HPV DNA detected by conventional PCR. RT-PCR: real-time polymerase chain reaction; HMBS: hydroxymethylbilane synthase gene; HR-HPV: high-risk human papillomavirus; CIN: cervical intraepithelial neoplasia; CIN 1: cervical intraepithelial neoplasia 1; CIN 2+: cervical intraepithelial neoplasia 2 or 3.
The probes and quenchers used for real-time polymerase chain reaction
| Test | Viral type | Size (bp) | Probe | Quencher |
|---|---|---|---|---|
|
| HPV-16 | 78 | FAM | ZEN/IBFQ |
|
| HPV-18 | 80 | Cy5 | IBRQ |
| HPV-31 | 78 | HEX | ZEN/IBFQ | |
|
| HPV-33 | 78 | FAM | ZEN/IBFQ |
| HPV-45 | 76 | Cy5 | IBRQ | |
|
| HPV-58 | 109 | HEX | ZEN/IBFQ |
|
| 76 | FAM | ZEN/IBFQ |
Four parallel duplex real-time PCRs were performed per patient. Probe design for each viral type and HMBS was adjusted based on the types included in each reaction.
HPV: human papillomavirus; FAM: 6-carboxyfluorescein; Cy5: FluoroLink mono reactive dye Cy5; HEX: hexachlorofluoresceine; HMBS: hydroxymethylbilane synthase; ZEN/IBFQ: ZEN and Iowa Black FQ; IBRQ: Iowa Black RQ.
The distribution of socio-demographic characteristics and risk factors
| Characteristic | Categories | n | % | With CIN (n = 59) | Without CIN (n =114) | p | ||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | |||||
|
|
| 29 | 16.76 | 11 | 18.64 | 18 | 15.79 | 0.493 |
|
| 54 | 31.21 | 21 | 35.59 | 33 | 28.95 | ||
|
| 90 | 52.02 | 27 | 45.76 | 63 | 55.26 | ||
|
|
| 65 | 37.57 | 32 | 54.24 | 33 | 28.95 |
|
|
| 108 | 62.43 | 27 | 45.76 | 81 | 71.05 | ||
|
|
| 7 | 4.05 | 3 | 5.08 | 4 | 3.51 | 0.691 |
|
| 166 | 95.95 | 56 | 94.92 | 110 | 96.49 | ||
|
|
| 155 | 89.06 | 53 | 89.83 | 102 | 89.47 | 0.942 |
|
| 18 | 10.40 | 6 | 10.17 | 12 | 10.53 | ||
|
|
| 1 | 0.58 | 1 | 1.69 | 0 | 0.00 | 0.094 |
|
| 82 | 47.40 | 22 | 37.29 | 60 | 52.63 | ||
|
| 74 | 42.77 | 28 | 47.46 | 46 | 40.35 | ||
|
| 10 | 5.78 | 6 | 10.17 | 4 | 3.51 | ||
|
| 6 | 3.47 | 2 | 3.39 | 4 | 3.51 | ||
|
|
| 17 | 9.83 | 4 | 6.78 | 13 | 11.40 | 0.673 |
|
| 20 | 11.56 | 7 | 11.86 | 13 | 11.40 | ||
|
| 8 | 4.62 | 4 | 6.78 | 4 | 3.51 | ||
|
| 126 | 72.83 | 43 | 72.88 | 83 | 72.81 | ||
|
| 2 | 1.16 | 1 | 1.69 | 1 | 0.88 | ||
|
|
| 159 | 91.91 | 52 | 88.14 | 107 | 93.86 | 0.191 |
|
| 14 | 8.09 | 7 | 11.86 | 7 | 6.14 | ||
|
|
| 146 | 84.39 | 49 | 83.05 | 97 | 85.09 | 0.726 |
|
| 27 | 15.61 | 10 | 16.95 | 17 | 14.91 | ||
|
|
| 41 | 23.70 | 10 | 16.95 | 31 | 27.19 | 0.133 |
| ≥ | 132 | 76.30 | 49 | 83.05 | 83 | 72.81 | ||
|
|
| 72 | 41.62 | 26 | 44.07 | 46 | 40.35 | 0.868 |
|
| 84 | 48.55 | 27 | 45.76 | 57 | 50.00 | ||
|
| 17 | 9.83 | 6 | 10.17 | 11 | 9.65 | ||
|
|
| 65 | 37.57 | 19 | 32.20 | 46 | 40.35 | 0.697 |
|
| 52 | 30.06 | 15 | 25.42 | 22 | 19.30 | ||
|
| 19 | 10.98 | 18 | 30.51 | 34 | 29.82 | ||
|
| 37 | 21.39 | 7 | 11.86 | 12 | 10.53 | ||
|
|
| 4 | 2.31 | 1 | 1.69 | 3 | 2.63 | 0.326 |
|
| 76 | 43.93 | 28 | 47.46 | 48 | 42.11 | ||
|
| 74 | 42.77 | 27 | 45.76 | 47 | 41.23 | ||
|
| 19 | 10.98 | 3 | 5.08 | 16 | 14.04 | ||
|
|
| 82 | 47.40 | 27 | 45.76 | 55 | 48.25 | 0.818 |
|
| 68 | 39.31 | 25 | 42.37 | 43 | 37.72 | ||
|
| 23 | 13.29 | 7 | 11.86 | 16 | 14.04 | ||
|
|
| 137 | 79.19 | 47 | 79.66 | 90 | 78.95 | 0.913 |
|
| 36 | 20.81 | 12 | 20.34 | 24 | 21.05 | ||
Values in bold = p < 0.05.
*The minimum average monthly income (2014 rate) would be roughly US $300.
p = p value; CIN: cervical intraepithelial neoplasia; STD: sexually transmitted disease.
Type-specific HR-HPV viral load distribution by category
| HPV type | n | % | With CIN (n = 59) | Without CIN(n = 114) | p | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative | Low viral load | High viral load | Negative | Low viral load | High viral load | ||||||||||
| n | % | n | % | n | % | n | % | n | % | n | % | ||||
|
| 86 | 49.71 | 25 | 42.37 | 12 | 20.34 | 22 | 37.29 | 62 | 54.39 | 13 | 11.40 | 39 | 34.21 | 0.186 |
|
| 117 | 67.63 | 18 | 30.51 | 10 | 16.95 | 31 | 52.54 | 38 | 33.33 | 18 | 15.79 | 58 | 50.88 | 0.928 |
|
| 71 | 41.04 | 40 | 67.80 | 1 | 1.69 | 18 | 30.51 | 62 | 54.39 | 3 | 2.63 | 49 | 42.98 | 0.257 |
|
| 14 | 8.09 | 54 | 91.53 | 0 | 0.00 | 5 | 8.47 | 105 | 92.11 | 1 | 0.88 | 8 | 7.02 | 0.846 |
|
| 67 | 38.73 | 36 | 61.02 | 9 | 15.25 | 14 | 23.73 | 70 | 61.40 | 10 | 8.77 | 34 | 29.82 | 0.366 |
|
| 56 | 32.37 | 42 | 71.19 | 7 | 11.86 | 10 | 16.95 | 75 | 65.79 | 16 | 14.04 | 23 | 20.18 | 0.772 |
|
| 159 | 91.91 | 4 | 6.78 | 8 | 13.56 | 47 | 79.66 | 10 | 8.77 | 12 | 10.53 | 92 | 80.70 | 0.777 |
HPV DNA load: categorised as ≤ 0 = negative. 0 < VL ≤ 105 HPV copies = low viral load. >105 HPV copies = high viral load.
*HR-HPV: high risk-human papillomavirus, infection by at least one high-risk viral type from the 6 analysed here.
HPV: human papillomavirus; CIN: cervical intraepithelial neoplasia; p = p value.
Figure 2Distribution of viral load for 6 HR-HPV types in both groups of patients. A. Absolute viral load. B Normalised viral load. The dotted line indicates the median; the box represents the interquartile range (IQR). The whiskers extending from the boxes are the upper and lower limits. Diamond markers represent extreme values. No statistically significant differences were observed regarding DNA load distribution of each HPV type between both groups of patients (Mann–Whitney U test). CIN: cervical intraepithelial neoplasia.
Distribution of 6 HR-HPV types’ viral load regarding biopsy results
| Viral type | Negative (n = 28) | CIN 1 (n = 16) | CIN 2+ (n = 1) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| % (n) | Viral load, median (IQR) | % (n) | Viral load, median (IQR) | % (n) | Viral load, median (IQR) | ||||
| Absolute | Normalised* | Absolute | Normalised* | Absolute | Normalised* | ||||
|
| 66.67 (22) | 6.42 (1.69) | 1.79 (0.54) | 57.89 (11) | 6.77 (3.04) | 1.69 (0.64) | 0 | n/a | n/a |
|
| 66.67 (22) | 6.29 (1.34) | 1.84 (0.51) | 68.42 (13) | 6.61 (2.28) | 1.67 (1.79) | 100 (1) | 7.02 (n/a) | 2.07 (n/a) |
|
| 30.30 (10) | 8.51 (1.90) | 2.39 (0.38) | 31.58 (6) | 9.69 (6.00) | 3.50 (2.17) | 0 | n/a | n/a |
|
| 3.03 (1) | 6.75 (n/a) | 1.98 (n/a) | 10.53 (2) | 8.48 (1.70) | 2.37 (2.06) | 100 (1) | 10.57 (n/a) | 3.13 (n/a) |
|
| 51.52 (17) | 6.13 (2.95) | 1.79 (1.00) | 42.11 (8) | 6.24 (1.17) | 1.61 (0.80) | 0 | n/a | n/a |
|
| 21.21 (7) | 5.93 (3.89) | 2.14 (2.35) | 36.84 (7) | 6.12 (0.34) | 1.75 (0.28) | 0 | n/a | n/a |
|
| 94.34 (31) | 6.37 (1.20) | 2.06 (0.63) | 94.74 (18) | 6.77 (2.97) | 2.12 (1.37) | 100 (1) | 8.80 (n/a) | 2.60 (n/a) |
Absolute and normalised viral loads were both log10 transformed.
*HPV copies/cell = number of HPV copies/(number of HMBS copies/2).
**HR-HPV: high risk-human papillomavirus, infection by at least one high-risk viral type from the 6 analysed here.
HPV: human papillomavirus; CIN: cervical intraepithelial neoplasia; CIN 1: cervical intraepithelial neoplasia 1; CIN 2+: cervical intraepithelial neoplasia 2 or 3; n/a: not applicable.
Conditional logistic regression model
| HPV type | Viral load | With CIN / without CIN | Crude OR (95%CI) | Adjusted OR* | 95%CI |
|---|---|---|---|---|---|
|
|
| 25/62 |
| ||
|
| 12/13 | 2.19 (0.88–5.43) |
| ||
|
| 22/39 | 1.27 (0.64–2.50) |
| ||
|
|
| 18/38 |
| ||
|
| 10/18 | 1.14 (0.45–2.89) | 1.72 | 0.52–5.69 | |
|
| 31/58 | 1.06 (0.52–2.17) | 1.77 | 0.68–4.63 | |
|
|
| 40/62 |
| ||
|
| 1/3 | 0.52 (0.04–6.29) | 0.15 | 0.01–2.26 | |
|
| 18/49 | 0.60 (0.32–1.14) |
| ||
|
|
| 54/105 |
| ||
|
| 0/1 | 0.00 (0 - .) | 0 | 0 - . | |
|
| 5/8 | 1.43 (0.45–4.50) | 1.67 | 0.44–6.28 | |
|
|
| 36/70 |
| ||
|
| 9/10 | 1.53 (0.60–3.92) | 2.94 | 0.92–9.44 | |
|
| 14/34 | 0.79 (0.38–1.67) | 1.13 | 0.43–2.96 | |
|
|
| 42/75 |
| ||
|
| 7/16 | 0.83 (0.32–2.11) | 0.73 | 0.23–2.31 | |
|
| 10/23 | 0.83 (0.37–1.83) | 0.86 | 0.35–2.12 | |
|
|
| 4/10 |
| ||
|
| 8/12 | 1.73 (0.40–7.47) | 1.01 | 0.23–4.50 | |
|
| 47/92 | 1.18 (0.35–4.00) | 1.39 | 0.25–7.81 |
Values in bold = p < 0.05.
*Adjusted for origin, ethnicity, age at first intercourse and number of viral types.
**HR-HPV: high-risk-human papillomavirus, infection by at least one high-risk viral type from the 6 analysed here (viral load = sum of viral loads of HPV types detected/ number of HPV types detected.
HPV: human papillomavirus; CIN: cervical intraepithelial neoplasia; VL: viral load; OR: odds ratio.